Kornimate/medical-research-clean huggingface dataset:
impact of respiratory allergy on response to initiation of biotherapy in severe asthma in adult severe asthmatic patients followed at poitiers university hospital on biotherapy

Conditions: Severe Asthma; Biotherapy; Respiratory Allergy

Summary: the aim of this study is to take stock of the situation of adult patients with severe asthma on biotherapy, followed up at poitiers university hospital, and in particular to increase our knowledge of factors predictive of response to biotherapy. the main aim is to improve the management of adult severe asthma patients treated with biotherapy, according to their allergic status.


Eligibility criteria:
inclusion criteria: * severe asthma patient on biotherapy * age \> or = 18 years * follow-up at poitiers university hospital exclusion criteria: * absence of allergological assessment * patient's refusal to participate in study
comparison of translocator protein expression and binding activity in normal tissue versus non melanotic malignancy

Conditions: Squamous Cell Carcinoma; Basal Cell Carcinoma

Summary: translocator protein (tspo) is a intracellular protein that is found primarily in the outer membrane of the mitochondria that is encoded by the tspo gene. it has been found that tspo expression in the skin correlates with cell proliferation and differentiation. many studies have shown that tspo overexpression in solid malignancies such as in ovarian cancer, colon cancer, and others, was also found to correlate with more aggressive cancer behavior. working hypothesis and aims: previous studies described an aberrant expression of tspo levels in solid malignancies as compared to normal tissues. it is assumed that this aberration can be found in cuntaneous malignancies as well. the occurrence of this aberration may lead to the understanding of the mechanism of tspo involment in the cutaneous malignancy, and in malignancies in general. methods: the study will be carried out on surgically resected skin lesions suspected to scc or bcc, which will be removed as part of the surgical routine treatment. the excision will be made in elliptic shape including the lesion and a part of normal skin surrounding it. a sample will be taken from the central part of the lesion and from the external extremity of the normal tissue. western blot will be conducted to detect the expression of tspo. binding activity with the tspo specific ligandwill also be determined. expected results: we expect to observe either (a) a higher level of tspo expression and a lower binding activity in malignant tissue compared with healthy control tissue or (b) a higher level of tspo expression and a lower binding activity in malignant tissue compared with healthy control tissue. importance: until today, only a very small number of studies have examined tspo in cutaneous malignancies, and these only examined tspo expression. our study will also measure the binding activity of tspo in cutaneous malignant tissues compared to normal tissues


Eligibility criteria:
inclusion criteria: * clinical diagnosis of basal cell carcinoma or squamous cell carcinoma exclusion criteria: * non-compliance with inclusion criteria

Keywords: translocator protein basal cell carcinoma squamous cell carcinoma malignancy
efficacy of purslane in treatment of oral lichen planus

Conditions: Lichen Planus, Oral

Summary: oral lichen planus (olp) is a chronic inflammatory disease whose prevalence in the general population is 0.5 -2.2%.oral lesions in olp are chronic, rarely undergo spontaneous remission. patients with olp had significantly increased risk of oral squamous cell carcinoma, irrespective of the clinical type of olp and therapy. there is currently no cure for olp. previous study demonstrated a decreased antioxidant defence and increased oxidative damage to lipids.dna and proteins in lichen planus. this oxidative modifications point to pathophysiological alterations mainly within the basal cell layers of epidermis and at the dermoepidermal junction. purslane is an excellent source of vitamin a,c and e and essential amino acids, has been described as a power food of the future because of its high nutritive and antioxidant properties. the purpose of the study was to determined the efficacy of purslane in the treatment of oral lichen planus.

oral lichen planus is a chronic common inflammatory disorder affecting stratified squamous epithelia. the majority problem of olp is development of oral squamous cell carcinoma , irrespective of the clinical type of olp and therapy. previous study demonstrated a decreased antioxidant defence and increased oxidative damage to lipids, dna and proteins in lichen planus .this oxidative modifications point to pathophysiological alterations mainly within the basal cell layers of epidermis and at the dermoepidermal junction. so oxidative stress could be effective in pathogenesis of olp. purslane is an excellent source of vitamin a,c and e and essential amino acids, has been described as a power food of the future because of its high nutritive and antioxidant properties. purslane also decreased the level of tnf-α and il6, that are responsible for up-regulated adhesion molecules (in olp lymphocyte t (t cell) recruited and retained in sub mucosa through receptors to endothelial adhesion molecule. and basal keratinocytes undergo apoptosis). the purpose of the study was to determined the efficacy of purslane in the treatment of oral lichen planus.

Eligibility criteria:
inclusion criteria: * biopsy confirmed symptomatic oral lichen planus: who histological criteria in combination with clinical appearance will be used for diagnosis * patients who had symptoms such as burning sensation, pain * patients not on any immunosuppressive or immunomodulatory treatment. in case they were,then such treatment should be stopped and a washout period of 1 month was given. * patients of both sexes between 30 to 70 year's old * patients who gave written informed consent * patients who were willing for evaluation in second week after therapy and every 1 month up to 6 months exclusion criteria: * the presence of histological signs of dysplasia * patients suffering from any localized or systemic disease * renal disease patients * pregnant patients * patients who can not continue the study for private or social reasons * patients who used lichenoid reaction including drugs

Keywords: antioxidant oral lichen planus treatment purslane
structural orbital changes in anophthalmic socket syndrome

Conditions: Anophthalmos; Acquired; Anophthalmic Socket Syndrome

Summary: understand better the aetiology and physiopathogenesis of anophthalmic socket syndrome.


Eligibility criteria:
inclusion criteria: * age 18 years or older * unilateral anophthalmic socket syndrome (superior sulcus grading 0 till 4) * enucleation/evisceration with primary implant more than 5 years ago * after informed consent exclusion criteria: * mri absolute and relative contraindications such as metallic fragments or metallic containing devices, * history of orbital trauma, previous anophthalmic socket and eyelid surgery, inflammation, infection, buphthalmos, congenital anophthalmos and radiation
how much opioids do you need after your emergency department visit

Conditions: Acute Pain

Summary: pain is one of the most common complaints in emergency department (ed) and is still often poorly managed. a major prospective multicenter study reported that 74% of patients that had a pain complaint at ed triage are discharged in moderate to severe pain. accordingly, physicians frequently prescribed analgesic after discharged for these patients, and opioid is given in 29% of ed visits involving pain complaints. however, few studies evaluate pain management after ed discharge: the frequency and length of opioids prescriptions, the opioids quantity taken by the patients, are the patients relieved and satisfied by these pain treatments, what are the adverse effects associated with the use of these medications, and what are the chances of developing addiction? the primary aim of this study is to determine the required minimal opioids prescription for patients treated for acute pain after being discharge from the ed. secondary objectives include: 1) monitor the patients' adverse events during opioids treatment; 2) evaluate the patients' level of pain relief associated with their respective opioids treatment; 3) determine the patients' level of addiction following post-ed opioids treatments. the design of the project is a prospective observational cohort study. a cohort of consecutive ed patients aged 18 or more with an initial pain at triage of 4 or more and discharged from the ed in less than 48 hours with a prescription of opioid will be asked to participate in the study. patients will be excluded if there is ongoing treatment for a pre-existing chronic pain condition or if they used opioid drugs in the past year. research nurses will contact the patients by phone at three follow-up time points (1 week, 1 month, and 3 months). follow-up phone interviews will evaluate pain intensity as well as pain treatment satisfaction (0-10 nrs), monitor adverse events, and investigate possible opioids addiction (sows: subjective opioid withdrawal scale). during these interviews, the nurses will also question the patients about their daily opioids usage and if they were relieved from pain. this study will provide the base for future guidelines regarding the prescription of opioids treatment for specific pathology encountered in ed. it will also give indications on how to adjust the treatments according to adverse events and the level of addiction experienced by patients.


Eligibility criteria:
inclusion criteria: * 18 years and older * pain level at 4 or greater at triage * acute pain (2 weeks or less) * opioids prescription at discharge exclusion criteria: * language barrier * pregnancy * treated for chronic pain * hospital stay greater than 48 hours
contingency management for cannabis use for persons with hiv

Conditions: Marijuana; HIV Infections

Summary: the purpose of this study is to determine the feasibility and impact of 28-days of monitored abstinence from cannabis use on symptoms of depression and anxiety, pain, sleep, cannabis use withdrawal, hiv viral load and biomarkers of systemic inflammation among plwh and who use cannabis regularly (weekly or more often). this will be a single arm pilot feasibility trial involving a contingency management program to induce cannabis abstinence. specifically, the contingency management program will provide motivational (monetary) incentives to participants who achieve biochemically verified cannabis abstinence. over the 28-days of this pilot feasibility trial, participants will attend seven study visits. during these visits, participants will complete survey questionnaires to assess sociodemographic, psychosocial, and behavioral factors. in addition, participants will provide blood and urine specimens for testing and quantitation of hiv viral load, biomarkers of systemic inflammation and for the detection of cannabis and other drugs of abuse.


Eligibility criteria:
inclusion criteria: * hiv-positive (confirmed via hiv medication or relevant hiv labs in subject's name) * self-report of cannabis use at least once per week in the 6-month period prior to consent * provide a positive urine toxicology (utox) screen for cannabis * not seeking treatment for cannabis use * willing to stop using cannabis for 28 days and attend eight study visits over six weeks. * ability and willingness to provide inform consent * english fluency exclusion criteria: * currently receiving treatment for cannabis or other drug use disorder * diagnosed or receiving treatment for a current major depressive or anxiety disorder * diagnosed with any current alcohol or substance use disorder (excluding nicotine) using the structured clinical interview for clinical disorders (scid) interview (22) * positive utox screen for opioids * having a medical, psychiatric, occupational, or other condition that, in the judgment of the study physician, would make participation difficult or unsafe.
effect of stablor on visceral fat loss in patients with a metabolic syndrome

Conditions: Metabolic Syndrome

Summary: the purpose of the study is to evaluate the impact of the intake of a dietary supplement stablor™ on the change of the abdominal visceral fat mass in patients with a metabolic syndrome.


Eligibility criteria:
inclusion criteria: * with a body mass index (bmi) more than or equal to 25 kg/m² and less than 40 kg/m², * with a metabolic syndrome characterized by a a waist circumference of more than 94 cm for the males (90 cm for south-asians, chinese and japanese) and more than 80 cm for the females, and at least 2 of the following criteria : * arterial blood pressure \> or = 130 mmhg (systolic) and/or more than or equal to 85 mmhg (diastolic) or stabilized with treatment for at least 6 months, * fasting glycemia \> or = 1 g/l or 5.6 mmol/l or stabilized with treatment for at least 6 months and non-diabetic \< 1.26 g/l, * triglycerides \> or = 1.5 g/l or 1.71 mmol/l or stabilized with treatment for at least 6 months, * hdl cholesterol \<0.40 g/l or 1.03 mmol/l (males) and \<0,5 g/l or 1.29 mmol/l (females) or stabilized with treatment for at least 6 months. exclusion criteria: * pregnant (positive pregnancy test at the selection visit or breast-feeding woman, * woman of childbearing potential without an efficient contraception method, the above information is not intended to contain all considerations relevant to a patient's potential participation in the clinical trial
pharmacogenomic study realized on "non-small cell lung carcinoma"

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: the purpose of this study is to correlate molecular genetic profile with response to chemotherapy in case of primary chemotherapy treatment for non-small cells lung carcinoma.

lung carcinoma will be the fifth death cause in the world in 2020. in europe it causes more deaths than carcinoma of breast, colon and prostate combined so it is a public healthcare priority. applying high throughput molecular analysis technologies to pharmacogenomics could improve lung carcinoma care strategies. the study hypothesis is that the determination of the genomic and proteomic profiles of non-small cell lung carcinoma patients will allow treatment targeting , improving treatment efficacy and tolerance. in order to carry out this study, the five thoracic oncology centers of the rhône-alpes region will collaborate with several inserm (french national research institute) units and new biotechnology companies. the primary objective of this study is to correlate molecular genetic profile with response to chemotherapy in cases of primary chemotherapy treatment for non-small cell lung carcinomas. biological samples will be collected before and during patient care to correlate clinical evolution (response and tolerance) with: * circulating cell polymorphism profile * proteomic profile * genetic and epigenetic modifications of genes involved in dna repair, drugs metabolism, apoptosis cell regulation mechanisms, and cell mobility and adhesion mechanisms. the main judgment criteria will be response to chemotherapy correlated with patient's biological profile. second judgment criteria will be overall survival and hematology toxicity which will be evaluated each new cycle of chemotherapy. the second purpose of this study is to validate less invasive methods of sampling using blood, expectoration, urine, fixed biopsies and lungs tapping, as a substitute to the current reference (frozen tumor), which is out of reach in clinical examination. this will contribute to setting of a multicentric resources bank, to define targets for new drugs and to develop oligoarrays allowing adapted chemotherapies. two previous studies (1800 and 500 patients respectively) have already been carried out, data and samples are available. for this study, 600 patients will be included over 3 years.

Eligibility criteria:
inclusion criteria: * patient older than 18 suffering from non-small-cell lung carcinoma * patient treated by chemotherapy with platinum salt * every stage tnm classification * no previous chemotherapy * one measurable lesion out of nervous central system at least * performance status from 0 to 2 on ecog scale * life expectancy \> 12 weeks exclusion criteria: * previous or concomitant carcinoma over 5 last years * concomitant radiotherapy * cardiac disease

Keywords: carcinoma, non-small-cell lung pharmacogenomic
evaluation of efficacy, safety and molecular mechanism of pentoxifylline supplementation in patients with hepatic and obstructive jaundice

Conditions: Hepatobiliary Disorders

Summary: investigating the efficacy, safety, and molecular mechanism of pentoxifylline supplementation in improving elevated direct bilirubin level and liver function tests in patients with hepatic and post-hepatic jaundice


Eligibility criteria:
inclusion criteria: * patients age 18-70 years old. * patients diagnosed with jaundice and increased level direct bilirubin ≥ 3 mg/dl. exclusion criteria: * pregnancy. * nursing mothers. * patients with increased indirect bilirubin level. * patients who have gilbert syndrome or crigler najjar syndrome. * patients with child paugh c score (10-15 point). * history of intolerance and hypersensitivity to pentoxifylline or to xanthine derivatives such as caffeine, theophylline. * recent hemorrhage. * patients who have risk factors potentially complicated by hemorrhage. * taking anticoagulants or antiplatelet therapy.

Keywords: jaundice pentoxifylline tac tnf-α bilirubin
gut microbiota and sepsis-associated acute kidney injury

Conditions: Sepsis; Acute Kidney Injury

Summary: sepsis has emerged as one of the important life-threatening infectious diseases with high morbidity and mortality. sepsis-associated kidney injury (saki) is one of the most common and serious complications of sepsis. it has been found that intestinal flora may affect the occurrence and development of a variety of diseases, and may also affect the pathogenesis of multiple saki, which is also regulated by host genetic factors. therefore, the investigators speculate that gut microbiota composition may be associated with susceptibility to saki, and there are no studies reporting the association between gut microbiota and saki. the investigators intend to carry out a multicenter study in conjunction with the department of intensive care of qinghai provincial people's hospital. the structure and function of intestinal flora in septic patients with renal injury and septic patients less susceptible to renal injury are studied by 16s rdna amplicon sequencing technology. the differences in composition, diversity and structural stability of intestinal flora between the two groups are analyzed to explore the genera that play a key role in the occurrence of the disease. by analyzing the differences between renal injury and inflammation levels in each group, the correlation between intestinal flora and saki, the possible influencing links involved, and the related factors affecting the prognosis of saki were revealed. the results of this study are helpful to further elucidate the pathogenesis of saki and provide new ideas and methods for the prevention and treatment of saki.


Eligibility criteria:
inclusion criteria: * age≥18 years；meet the sepsis definition and diagnostic criteria of sepsis-3.0 guidelines；no previous history of hypertension or diabetes; no underlying kidney disease such as nephrotic syndrome, no history of rheumatic immune system disease; normal renal function before onset. exclusion criteria: * patients with hypertension, diabetes, coronary heart disease, tumor, rheumatism immune system disease and other related diseases that may cause kidney injury; patients with abnormal renal function before onset; patients with nephrotic syndrome and other underlying kidney disease; long-term oral administration of drugs with kidney injury; previous history of gastrointestinal surgery; no diarrhea related diseases or other gastrointestinal diseases in the past 1 month; the use of antibiotics and probiotics in the past 1 month; exclusion of other primary or secondary renal damage factors.

Keywords: sepsis-associated kidney injury gut microbiota metagenome prognosis
arthroscopic scapholunate ligament reconstruction

Conditions: Scapholunate Dissociation

Summary: arthroscopical reconstruction of the volar and dorsal part of the scapholunate ligament as treatment for complete scapholunate ligament injury, but reducible carpal malalignment. this prospective study aims to evaluate the clinical and functional outcome of this technique on the short and middle term

classical arthroscopic techniques for scapholunate instability consist of debridement, thermal shrinkage, and percutaneous pinning. good results are obtained in acute lesions or in chronic partial tears, but they are less predictable when the lesion is complete, because of the poor healing capacity of the scapholunate ligament and because it is not possible to perform an anatomic ligamentous reconstruction with these techniques. open techniques are thus required for reconstruction, but they damage the soft tissues. corella et al. published a description and cadaver study of an arthroscopic ligamentoplasty, trying to combine the advantages of arthroscopic techniques (minimally invasive surgery) and open techniques (reconstruction of the ligament). with this approach, it is possible to reconstruct the dorsal scapholunate ligament and the secondary stabilizers while causing minimal damage to the soft tissues and avoiding injury to the posterior interosseous nerve and detachment of the dorsal intercarpal ligament. arthroscopic scapholunate volar and dorsal ligament reconstruction achieves an anatomic reconstruction to provide a strong construct for early mobilization.

Eligibility criteria:
inclusion criteria: * scapholunate dysfunction, complete irrepairable lesion of the sl ligament and the secondary stabilizers (rsc-lrl-srl) ewas stage 4-5, no arthritis, with reducible malalignment * 18 - 65 years exclusion criteria: * - associated lesions, fractures * neurological disorder affecting the upper limb, history of wrist lesion involving the same wrist, dementia, substance abuse, severe psychiatric disorder and previous injured contralateral wrist

Keywords: scapholunate instability reconstruction
pet and mri imaging of brain tumors using [18f]parpi

Conditions: Brain Tumor; Brain Cancer

Summary: this study is to collect data about how 18fparpi can be used together with pet/positron emission tomography and mri/magnetic resonance imaging scans to take pictures of brain cancer


Eligibility criteria:
inclusion criteria: * patients with new or suspected recurrent brain tumors (including suspected recurrent brain tumors showing growth from any preceding scan) * age \>/= 18 years * minimum at least one brain lesion size \>/= 1.5cm diameter * scheduled to undergo treatment at msk * willingness to sign informed consent * able to receive intravenous gadolinium contrast per msk department of radiology guidelines exclusion criteria: * any contraindication to 3t mri (pet/mr scanner is 4.0 tesla) * pregnancy or breast-feeding women

Keywords: brain cancer 18fparpi pet scan mri memorial sloan kettering cancer center 19-311